

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Clamoxyl Ready-To-Use 150 mg/ml suspension for injection

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

<b>Active Substance</b>	<b>mg/ml</b>
Amoxicillin (As Amoxicillin trihydrate)	150

For a full list of excipients please see section 6.1

### **3. PHARMACEUTICAL FORM**

Suspension for injection  
A white to off white oily suspension

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Dogs, cats, sheep, pigs and cattle

#### **4.2 Indications for use, specifying the target species**

For the treatment of infections caused by susceptible organisms in dogs, cats, sheep, pigs and cattle. The product is not effective against beta-lactamase producing organisms.

#### **4.3 Contraindications**

Not to be used in rabbits, guinea pigs, hamsters or gerbils.  
The suspension is not suitable for intravenous or intrathecal administration.

#### **4.4 Special warnings for each target species**

The product is not effective against beta-lactamase producing organisms. Complete cross-resistance has been shown between amoxicillin and other penicillins, in particular amino-penicillins.

Use of the product/amoxicillin should be carefully considered when antimicrobial susceptibility testing has shown resistance to penicillins because its effectiveness may be reduced.

#### 4.5 Special precautions for use

i) Special precautions for use in animals

Do not use in animals with known sensitivity to the active substance.

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local epidemiological information. This product does not contain an antimicrobial preservative.

ii) Special precautions to be taken by the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self injection.

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and vice versa. Allergic reaction to these substances may occasionally be serious.

Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.

Handle this product with great care to avoid exposure taking all recommended precautions.

If you develop symptoms following exposure, such as a skin rash, you should seek medical advice and show the doctor this warning. Swelling of the face, lips or eyes or difficulty with breathing, are more serious symptoms and require urgent medical attention.

Wash hands after use.

#### 4.6 Adverse reactions (frequency and seriousness)

Use of the product may occasionally result in local tissue reaction.

Penicillins and cephalosporins may cause hypersensitivity (allergy, allergic skin reactions) after use. Allergic reactions may occasionally be serious (anaphylaxis).

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

None

#### **4.8 Interaction with other medicinal products and other forms of interaction**

It is not generally recommended to use bactericidal and bacteriostatic antibiotics at the same time.

Beta-lactam antibiotics are known to interact with antibiotics with bacteriostatic action such as chloramphenicol, macrolides, sulfonamides and tetracyclines. There is also synergic action of penicillins with aminoglycosides.

#### **4.9 Amounts to be administered and administration route**

The recommended dosage rate is 7 mg/kg bodyweight once daily for up to 5 days by subcutaneous (dogs, cats), or intramuscular (dogs, cats, sheep, pigs and cattle) injection.

If the volume to be given is greater than 15 ml (cattle) and 5 ml (sheep and pigs) the dose should be divided and the remaining should be injected in another site.

Shake the vial well to suspend the active ingredient before use.

Swab rubber septum and remove required volume aseptically.

Do not breach more than 40 times.

Massage the injection site after administration. Use a new anatomical site for repeated injections. To ensure the correct dosage, bodyweight should be determined as accurately as possible to avoid overdosing.

In common with other penicillin preparations hydrolysis takes place rapidly in the presence of water. It is important therefore that a dry syringe is used when extracting the suspension for injection to avoid contaminating the remaining contents of the vial with drops of water.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Amoxicillin is of a very low order of acute toxicity and is well tolerated by the parenteral route. Occasional injection site reactions may occur with the recommended dose, but no other adverse side effects are to be expected from accidental overdosing.

#### **4.11 Withdrawal periods**

**Meat and offal:** Cattle: 54 days  
Sheep: 47 days  
Pigs: 47 days

**Milk:** Cattle: 60 hours from the last treatment.  
Not to be used in sheep producing milk for human consumption.

## 5. PHARMACOLOGICAL PROPERTIES

**ATCVet Code:** QJ01CA04

Amoxicillin is a broad-spectrum semi-synthetic penicillin which is bactericidal *in vitro* against a wide range of Gram-positive and Gram-negative bacteria including the following: *Actinomyces* spp., *Bacillus* spp., *Bordetella bronchiseptica*, *Clostridium* spp., *Corynebacterium* spp., *Escherichia coli*, *Fusobacterium* spp., *Haemophilus* spp., *Leptospira* spp., *Moraxella* spp., *Pasteurella* spp., *Proteus* spp., *Salmonella* spp., Streptococci, Staphylococci (penicillin-sensitive strains).

The product is indicated for the treatment of infections caused by Amoxicillin-sensitive organisms in dogs, cats, sheep, pigs and cattle.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Polysorbate 80  
Aluminium Stearate  
Ethyl Oleate

### 6.2 Incompatibilities

None known

### 6.3 Shelf-life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening the immediate packaging: 28 days.

### 6.4 Special precautions for storage

Do not store above 25°C.  
Following withdrawal of the first dose, use the product within 28 days.  
Discard unused material.

### 6.5 Nature and composition of immediate packaging

Carton containing 6 100ml clear colourless type III glass vials with chlorobutyl bungs with an aluminium overseal.  
Carton containing 4 250ml clear colourless type II or type III glass vials with chlorobutyl bungs with an aluminium overseal.  
Not all pack sizes may be marketed.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

**8. MARKETING AUTHORISATION NUMBER**


Vm 42058/4016

**9. DATE OF THE FIRST AUTHORISATION**

03 December 1990

**10. DATE OF REVISION OF THE TEXT**

April 2022

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 08 April 2022